29/04/2026
What a successful event this year’s Royal Society of Medicine National Diabetic Eye Screening Conference has been.👏
A great location, a strong programme of talks and, most importantly, plenty of meaningful discussion around the future of diabetic eye screening and the role of advanced imaging - including the capabilities of the Canon Xephilio OCT-R1.
The conference covered four key areas shaping the future of screening and care:
👁️ Updates on the UK National Diabetic Eye Screening Programme, including uptake figures, increasing demand, workforce considerations and the continued rollout of OCT - alongside the introduction of AI-supported grading
👁️ The impact of new diabetes treatments, such as closed-loop systems and GLP-1 therapies, in reducing the incidence of diabetic retinopathy
👁️ How patients are managed following referral to Hospital Eye Services
👁️ Treatment approaches in advanced diabetic retinopathy, including laser, anti-VEGF therapy and vitrectomy
✅It’s clear that technology continues to play a vital role in improving patient pathways. At Sense Medical, we’re proud to support the rollout of OCT within screening programmes through the Canon Xephilio OCT-R1, alongside providing training and ongoing support to screening teams.
Ultimately, this helps enable earlier detection, more informed decision-making and faster access to treatment - improving outcomes and helping to protect patients’ sight.
We really valued the conversations we had with both existing users of our systems and new partners, and we’ll be following up with everyone we met over the coming days. 🤗
We look forward to continuing to support NHS screening programmes and private ophthalmology services with consistent diagnostic quality, robust support and effective training. Thank you for having us!